Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
about
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infectionExpression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acidPractical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIVThe macrophage: a therapeutic target in HIV-1 infectionHIV-1 functional cure: will the dream come true?Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cureUsing animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchUnderstanding HIV latency: the road to an HIV cureBryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent mannerEpigenetic regulation of HIV-1 latency by cytosine methylationEffects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaquesProspects for treatment of latent HIV.HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription.Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapySynergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication.Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS.Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI.Combinatorial latency reactivation for HIV-1 subtypes and variantsBET bromodomain inhibition as a novel strategy for reactivation of HIV-1Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic AcidValproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapyFinding a cure for HIV: will it ever be achievable?Innate and adaptive factors regulating human immunodeficiency virus type 1 genomic activation.Histone deacetylase inhibitors and HIV latency.Pharmaceutical approaches to eradication of persistent HIV infection.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor.Generation of HIV latency in humanized BLT mice.HIV RNA suppression and immune restoration: can we do better?Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapyStimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individualsSelective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis.Targeting HIV latency: pharmacologic strategies toward eradication.HIV-1 transcription and latency: an update.
P2860
Q21142645-88FAA757-E844-488B-8EA2-AB3CBEFB4998Q24596282-9987B073-6ED8-46BB-B2E7-C17C50FA8488Q24654112-8A05C095-07B5-49FA-928D-D9EE316C9623Q26823236-A7BB815A-AB20-4FA2-9851-1A18D8CD198FQ26865803-833D6813-C11E-4853-A67D-F42804242F3FQ26999858-8D1FA5C2-BBA4-445E-8455-1D98E99A4BFFQ28077662-1D5A122F-7C25-4B5B-87C5-A85C7A6450CDQ28085296-7EC285A6-1AB9-4F39-82E5-A4EB33D468B9Q28474468-E6295726-93F2-4F39-82C5-39F38C36F25DQ28475636-3F3F4D6B-8581-47FA-9F4D-971FB9106BCAQ28540858-72206F8C-C146-4DDE-B6A0-D5E2F5474A4DQ30424413-35EC96CC-691F-4231-A739-4A45F3CEDFF4Q30835037-DCCAAE72-A054-48D7-BB70-149BDADDC673Q33373073-CD7EDC1D-AC9F-4B7F-9063-25CFCDE52E7FQ33476165-76ADD6C0-BDC2-46D7-A230-6355F7487BD7Q33589167-C99DD164-6942-4781-90E8-2EBAA91450C7Q33610934-4F7085D8-0EBF-40A9-BF58-D24BE278BCC3Q33844698-C640BC0F-657D-4473-9145-F143CBE5E8F8Q33877492-6D7D51E3-7005-41BB-A800-07E931225997Q34032827-D06B5355-E39A-456B-8ADA-A0F185801DE6Q34132738-B3BF2172-E34D-4051-9C49-116972E10748Q34187225-2225236A-C35C-4E5D-9FC7-DF8571323315Q34249596-92B90CE4-CE34-4835-8415-90685B3C23DEQ34290545-70AEB8E1-A94A-454B-AD3B-B935D321BE95Q34567084-505D8559-4731-4634-A9D6-B6AAC0BE2CDDQ34671609-A19270CD-3BB5-4E00-9277-CF0A06247054Q34816844-9107019A-1862-4BFA-BF4A-5F5AF93073BCQ34941973-685F0AF9-6504-4594-AF6F-B8229CE5D06CQ35016964-3FAA11D9-6E0F-4FD9-8305-7D10EDB908C7Q35065109-25B4C487-B2A3-44A5-87EA-5ABB886738D6Q35666126-4BA70D75-6697-42FA-B8EA-F891D61FD98FQ35867173-6BE1CBF0-4188-44E5-B80C-7C21FB0CBB9CQ36379282-461EFD33-70F8-4399-9897-6169FE9F7D32Q36409885-0CBB6AC3-4E90-4697-858F-5647DAB83AB9Q36501927-7C004B1D-6E84-4CCD-97EF-162379274825Q36525896-09A8BC5B-18BF-426D-93EC-7EC7FE9A5C31Q36596027-F9AD7427-8869-4FC2-AB39-A331AD1A92CBQ36667599-66A3A376-319D-4DE4-B192-4F338B4A8D68Q36901950-0052B335-8E4F-4A2C-96E9-84F77A7793C1Q36976156-6D50A36A-1E6D-485C-BA28-E6BA894A115B
P2860
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
@en
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
@nl
type
label
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
@en
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
@nl
prefLabel
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
@en
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
@nl
P2093
P50
P356
P1476
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
@en
P2093
Janet D Siliciano
Joel E Gallant
Joseph Cofrancesco
Marc Callender
Richard D Moore
P304
P356
10.1086/511823
P407
P577
2007-01-30T00:00:00Z